ViruCure is biotech company developing an oncolytic-virus-based technology platform for the treatment of cancer. ViruCure has developed a product using viruses that recognize, target, and destroy cancer cells (Oncolytic virus).
The product is based on breakthrough research that has provided evidential proof of this concept in human terminal Glioblastoma patients (GBM). The virus extended the life of 33% of the patients, caused tumor shrinkage, and in some patients resulted in complete remission of the cancer. These results are dramatic in light of the fact that there has been no effective treatment for these types of tumors to date.
CEO & Co-Founder
Mr. Yoram Drucker is a Serial Israeli entrepreneur with 20 years experience in business development, fundraising, and executive involvement in Biotechnology sectors, including founding and developing three biotech publicly traded companies. He was previously involved in the development of two successful cell therapy technology firms, Brainstorm (NASDAQ:BCLI) where he served as COO in 2004 and CEO from 2005 to 2007, and was one of the founders of Pluristem (NASDAQ:PSTI) where he was a Director in 2004 and 2005.
Dr. Shay Tayeb
CTO & Co-Founder
Dr. Tayeb is a post-doctoral researcher and lecturer in the fields of molecular biology, microbiology, virology, and gene therapy. The focus of his research is NDV mechanisms in several tumor models. Dr. Tayeb has developed novel biological methods. Dr. Tayeb has published numerous, highly-cited papers in leading peer-reviewed medical journals, written a book chapter, and presented several abstracts at international conferences.